Baseline characteristics of unmatched and propensity score matched TNK and alteplase group
| Characteristic | Unmatched groups | Propensity score matched group | ||||
| TNK n=1113 | Alteplase n=2360 | P value | TNK n=1113 | Alteplase n=1113 | P value | |
| Demographics | ||||||
| Age, years, median (IQR） | 66 (58.5, 73) | 68 (60, 76) | 0.000 | 66 (58.5, 73) | 67 (58, 74) | 0.214 |
| Male, n, (%) | 713 (64.06%) | 1567 (66.4%) | 0.176 | 713 (64.06%) | 698 (62.71%) | 0.509 |
| Pre-mRS, median (IQR) | 0 (0, 0) | 0 (0, 0) | 0.006 | 0 (0–0) | 0 (0–0) | 0.595 |
| mRS=0, % | 1002 (90.03%) | 2041 (86.48%) | 1002 (90.03%) | 1008 (90.57%) | ||
| mRS=1, % | 66 (5.93%) | 194 (8.22%) | 66 (5.93%) | 64 (5.75%) | ||
| mRS=2, % | 32 (2.88%) | 76 (3.22%) | 32 (2.88%) | 35 (3.14%) | ||
| mRS=3, % | 7 (0.63%) | 26 (1.1%) | 7 (0.63%) | 3 (0.27%) | ||
| mRS=4, % | 6 (0.54%) | 21 (0.89%) | 6 (0.54%) | 3 (0.27%) | ||
| mRS score=5, % | 0 (0%) | 2 (0.08%) | 0 (0%) | 0 (0%) | ||
| Pre-mRS=0–1, n (%) | 1068 (95.96%) | 2235 (94.7%) | 0.110 | 1068 (95.96%) | 1072 (96.32%) | 0.66 |
| Risk factors, No. (%) | ||||||
| Smoking | 204 (18.33%) | 810 (34.32%) | 0.000 | 204 (18.33%) | 201 (18.06%) | 0.869 |
| Hypertension | 702 (63.07%) | 1538 (65.17%) | 0.228 | 702 (63.07%) | 675 (60.65%) | 0.239 |
| Diabetes mellitus | 201 (18.06%) | 683 (28.94%) | 0.000 | 201 (18.06%) | 212 (19.05%) | 0.549 |
| Dyslipidaemia | 57 (5.12%) | 378 (16.02%) | 0.000 | 57 (5.12%) | 74 (6.65%) | 0.126 |
| Atrial fibrillation | 90 (8.09%) | 342 (14.49%) | 0.000 | 90 (8.09%) | 87 (7.82%) | 0.814 |
| Previous history, No. (%) | ||||||
| Coronal heart disease | 118 (10.60%) | 284 (12.03%) | 0.218 | 118 (10.60%) | 107 (9.61%) | 0.439 |
| Heart failure | 12 (1.08%) | 54 (2.29%) | 0.015 | 12 (1.08%) | 19 (1.71%) | 0.205 |
| Ischaemic stroke/TIA | 159 (14.3%) | 462 (19.58%) | 0.000 | 159 (14.3%) | 170 (15.27%) | 0.511 |
| Concomitant medication, No. (%) | ||||||
| Antiplatelet drugs | 106 (9.52%) | 427 (18.09%) | 0.000 | 106 (9.52%) | 100 (8.98%) | 0.611 |
| Anticoagulant drugs | 39 (3.50%) | 69 (2.92%) | 0.358 | 39 (3.50%) | 19 (1.71%) | 0.008 |
| Clinical presentation at emergency | ||||||
| NIHSS score on admission, median (IQR) | 5 (3, 8) | 5 (3, 9) | 0.334 | 5 (3, 8) | 5 (3, 9) | 0.427 |
| Glucose, mmol/L, median (IQR) | 6.53 (5.6, 8.2) | 6.8 (5.6, 8.8) | 0.007 | 6.53 (5.6, 8.2) | 6.7 (5.6, 8.35) | 0.423 |
| Systolic blood pressure, median (IQR) | 146 (130, 160) | 146 (133, 162) | 0.023 | 146 (130, 160) | 143 (130,160) | 0.599 |
| Thrombolytic drug dose (mg/kg), median (IQR） | 0.25 (0.23, 0.25) | 0.9 (0.9, 0.9) | NA | 0.25 (0.23, 0.25) | 0.9 (0.9, 0.9) | NA |
| Thrombectomy, n (%) | 93 (8.36%) | 266 (11.27%) | 0.008 | 93 (8.36%) | 109 (9.79%) | 0.238 |
| Door to needle time, DNT, minutes, median (IQR) | 29 (21, 42) | 38 (27, 55) | 0.000 | 29 (21, 42) | 36 (25, 53) | 0.000 |
| Door to puncture time, DTP, minutes, median (IQR) | 110 (100, 167.5) | 154 (104.5, 210) | 0.001 | 110 (100, 167.5) | 132 (95, 207) | 0.0667 |
| Onset to treatment time, OTT, minutes, median (IQR) | 180 (123, 224.5) | 140 (102, 185) | 0.000 | 180 (123, 224.5) | 142 (100, 186) | 0.000 |
*Univariate comparison between TNK and alteplase.
BP, blood pressure; DNT, door to needle time; DTP, door to puncture; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OTT, onset to treatment time; TNK, tenecteplase.